CD8A and neoplasm: Pre-clinical studies in solid cancer have suggested that anti-PD-1 therapy cannot function in the absence of primed tumor antigen-specific CD8+ cytotoxic T cells which express high levels of PD-1 (exhausted phenotype) (2, 92, 93).